Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension

References

• Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335–2345.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346–2355.
   PubMed Web of Science ®Google Scholar
• Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160–2170.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Esler MD. Take a blood pressure pill or undergo renal denervation? Lancet. 2018;391(10137):2298–2300.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Fadl Elmula FEM, Persu A. Future of renal sympathetic denervation in the treatment of hypertension. J Am Coll Cardiol. 2019;73(13):1643–1645.
   PubMed Web of Science ®Google Scholar
• Sardar P, Bhatt DL, Kirtane AJ, et al. Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension. J Am Coll Cardiol. 2019;73(13):1633–1642.
   PubMed Web of Science ®Google Scholar
• Freis ED. Hemodynamics of hypertension. Physiol Rev. 1960;40:27–54.
   PubMed Web of Science ®Google Scholar
• Lund-Johansen P. Hemodynamic effects of antihypertensive agents. Can Med Assoc J. 1983;128(1):21–23.
   PubMed Web of Science ®Google Scholar
• Omvik P, Lund-Johansen P. Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. Cardiovasc Drugs Ther. 1993;7(2):193–206.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FE, Hoffmann P, Larstorp AC, et al. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63(5):991–999.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press. 2018;27(6):314–340.
   PubMed Web of Science ®Google Scholar
• Hjornholm U, Larstorp ACK, Andersen MH, et al. Directly observed therapy prior to ambulatory blood pressure measurement (DOT-HTN) in uncontrolled hypertensive patients - Effect on blood pressure, safety and patient perception. Blood Press. 2019;28(5):327–335.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FE, Rebora P, Talvik A, et al. A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients. J Hypertens. 2015;33(12):2534–2545.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Flack JM, Strobeck JE, et al. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. Ther Adv Cardiovasc Dis. 2010;4(1):5–16.
   PubMedGoogle Scholar
• Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39(5):982–988.
   PubMed Web of Science ®Google Scholar
• Faini A, Omboni S, Tifrea M, et al. Cardiac index assessment: validation of a new non-invasive very low current thoracic bioimpedance device by thermodilution. Blood Press. 2014;23(2):102–108.
   PubMed Web of Science ®Google Scholar
• Woltjer HH, Bogaard HJ, de Vries PM. The technique of impedance cardiography. Eur Heart J. 1997;18(9):1396–1403.
   PubMed Web of Science ®Google Scholar
• Osypka MJ, Bernstein DP. Electrophysiologic principles and theory of stroke volume determination by thoracic electrical bioimpedance. AACN Clin Issues. 1999;10(3):385–399.
   PubMedGoogle Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16(3):135–232.
   PubMed Web of Science ®Google Scholar
• Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013;62(3):526–532.
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903–1909.
   PubMed Web of Science ®Google Scholar
• DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.
   PubMed Web of Science ®Google Scholar
• Persu A, Azizi M, Jin Y, et al. Hyperresponders vs. nonresponder patients after renal denervation: do they differ? J Hypertens. 2014;32(12):2422–2427.
   PubMed Web of Science ®Google Scholar
• Azizi M, Sapoval M, Gosse P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–1965.
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219–227.
   PubMed Web of Science ®Google Scholar
• Vuignier Y, Grouzmann E, Muller O, et al. Blood pressure and renal responses to orthostatic stress before and after radiofrequency renal denervation in patients with resistant hypertension. Front Cardiovasc Med. 2018;5:42.
   PubMed Web of Science ®Google Scholar
• Talvik A, Rebora P, Heinpalu-Kuum M, et al. Non-invasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients: effects on home blood pressure in the BEAUTY study. Blood Press. 2018;27(6):368–375.
   PubMed Web of Science ®Google Scholar
• Pike TL, Elvebak RL, Jegede M, et al. Forearm vascular conductance during mental stress is related to the heart rate response. Clin Auton Res. 2009;19(3):183–187.
   PubMed Web of Science ®Google Scholar
• Eskas PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205.
   PubMed Web of Science ®Google Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
   PubMed Web of Science ®Google Scholar
• van Brussel PM, Eeftinck Schattenkerk DW, Dobrowolski LC, et al. Effects of renal sympathetic denervation on cardiac sympathetic activity and function in patients with therapy resistant hypertension. Int J Cardiol. 2016;202:609–614.
   PubMed Web of Science ®Google Scholar
• Ewen S, Cremers B, Meyer MR, et al. Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. J Hypertens. 2015;33(12):2519–2525.
   PubMed Web of Science ®Google Scholar
• Ott C, Franzen KF, Graf T, et al. Renal denervation improves 24-hour central and peripheral blood pressures, arterial stiffness, and peripheral resistance. J Clin Hypertens. 2018;20(2):366–372.
   Web of Science ®Google Scholar